On Monday, the U.S. Food and Drug Administration (FDA) made a significant stride in obesity treatment by approving a daily oral version of Novo Nordisk’s weight-loss medication, Wegovy. This new formulation introduces a pill that utilizes semaglutide, the same active ingredient found in both Wegovy and Ozempic, which have traditionally been administered via weekly injections. As obesity continues to be a pressing health issue in the United States, with approximately 1 in 8 adults currently using these medications, the approval marks a pivotal moment in expanding treatment options.
Dr. Jason Brett, the principal U.S. medical head for Novo Nordisk, expressed optimism regarding this development, stating, “We believe it will expand access and options for patients.” This sentiment is echoed by many healthcare professionals, as the injectable format has deterred some patients due to the discomfort or inconvenience associated with injections. The Wegovy pill is expected to be available by prescription in January, with a starting price of $149 for those paying out of pocket—a figure that aligns with a previous agreement made under the Trump administration.
Clinical trials have shown that the Wegovy pill results in weight loss comparable to its injectable counterpart, with participants experiencing an average weight reduction of 14% over 64 weeks versus a mere 2% for those on a placebo. In comparison, the injection demonstrated a slightly higher average weight loss of 15%. While these results are promising, they also highlight the nuances of patient experience and medication adherence.
The Wegovy pill, however, comes with specific instructions: it must be taken on an empty stomach with a minimal amount of water, and patients must refrain from eating, drinking, or taking other medications for 30 minutes afterward. This requirement raises questions about practical usability compared to Lilly’s forthcoming oral GLP-1 drug, orforglipron, which boasts more flexible administration without food restrictions. Financial analyst Evan Seigerman points out that such convenience could sway patient preferences, particularly for those seeking ongoing weight maintenance after initial success with injectable medications.
Despite the excitement surrounding these new oral options, some experts urge caution. Dr. Judith Korner, an endocrinologist at Columbia University, emphasizes the importance of evaluating new treatments based on their efficacy, safety, and cost. While the lower initial cost of the Wegovy pill is appealing, she notes that patients typically do not remain on the lowest dose for long, as the medications are designed to be titrated up to manage side effects. “The lowest dose is almost never the dose that people wind up being on,” she explains, pointing out that this is merely a starting point for many patients.
Moreover, the broader benefits of GLP-1 medications extend beyond weight loss; they have shown promise in improving cardiovascular health and reducing the risk of conditions like sleep apnea and liver dysfunction. Dr. Korner highlights these secondary benefits, stating, “As we start seeing these benefits, like for people who’ve had cardiac disease, that’s, to me, the exciting part.”
As the market for obesity treatments continues to evolve, the introduction of the Wegovy pill and Lilly’s upcoming orforglipron signifies a notable shift towards more accessible and patient-friendly options. However, the conversation surrounding their long-term effectiveness, cost implications, and practical usability is just beginning. For patients grappling with obesity, these developments could usher in a new era of treatment options, tailored to meet diverse needs and preferences.
Reviewed by: News Desk
Edited with AI assistance + Human research
